MILLENDO THERAPEUTICS的封面图片
MILLENDO THERAPEUTICS

MILLENDO THERAPEUTICS

生物技术

Ann Arbor，Michigan 1,175 位关注者

Relentlessly pursuing therapies that alleviate patient suffering due to orphan endocrine disease

关注

关于我们

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing’s Syndrome (CS).

网站
https://www.millendo.com/
所属行业
生物技术
规模
11-50 人
总部
Ann Arbor，Michigan
类型
私人持股
领域
biotech、pharmaceuticals和Endocrinology

地点

  • 主要

    301 N Main St

    US，Michigan，Ann Arbor，48104

    获取路线

  • 15, Chemin du Saquin

    FR，Auvergne-Rhone-Alpes，écully，69130

    获取路线

MILLENDO THERAPEUTICS员工

查看全部员工

相似主页

查看职位